Targets › TLR9
14 programs from 13 companies in 22 trials: 9 Phase 1, 9 Phase 2, 3 Phase 3, 1 Phase 4; Oncology, Gastroenterology, Ophthalmology; next expected readout Nov 2026.
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. (UniProt, Q9NR96)
Open in Phaseline: the race on TLR9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Taiwan University Hospital | Hydroxychloroquine Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 4 | Graves Ophthalmopathy; Steatohepatitis, Nonalcoholic | Jun 2027 |
| University of Oxford | Hydroxychloroquine Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 3 | Pneumonia; COVID-19 | Jan 2027 |
| NYU Langone Health | Hydroxychloroquine Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 3 | Systemic Lupus Erythematosus; Rheumatic Disease | Jan 2028 |
| National Cancer Institute (NCI) | CMP-001 TLR9 agonist | TLR9 | Phase 2 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Dec 2026 |
| Abramson Cancer Center at Penn Medicine | Hydroxychloroquine Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 2 | Breast Cancer Stage IIB; Breast Cancer | Jan 2027 |
| Medical University of South Carolina | Hydroxychloroquine Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 2 | Ovarian Cancer; Prostate Cancer Recurrent | May 2027 |
| Idera Pharmaceuticals | Tilsotolimod Toll-like receptor 9 agonist | TLR9 | Phase 2 | Solid Tumor; Malignant Melanoma | – |
| NYU Langone Health | CpG1018 TLR9 agonist | TLR9 | Phase 1 | Mild Cognitive Impairment | Nov 2026 |
| National Cancer Centre, Singapore | ACM-CpG CpG-B TLR9 agonist | TLR9 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| West Virginia University | Hydroxychloroquine sulfate Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 1 | Adenocarcinoma of the Pancreas | Jun 2027 |
| TriSalus Life Sciences | SD-101 TLR9 agonist | TLR9 | Phase 1 | Locally Advanced Pancreatic Adenocarcinoma; Hepatocellular Carcinoma | Sep 2027 |
| Brown University | ACM-CpG TLR9 agonist | TLR9 | Phase 1 | Malignant Ascites | Jul 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | CpG-ODN Toll-like receptor 9 (TLR9) agonist | TLR9 | Phase 1 | Lung Cancer | Jun 2029 |
| Xingchen Peng | Hydroxychloroquine Sulfate Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 1 | Radiation-induced Oral Mucositis | – |
Breast Cancer (2) Adenocarcinoma of the Pancreas (1) Breast Cancer Stage IIB (1) Graves Ophthalmopathy (1) Steatohepatitis, Nonalcoholic (1) Mild Cognitive Impairment (1) Advanced Solid Tumor (1) Solid Tumor (1) Malignant Melanoma (1) Ovarian Cancer (1) Prostate Cancer Recurrent (1) Clinical Stage III Cutaneous Melanoma AJCC v8 (1)
small molecule (7), mixed (6)
NYU Langone Health (2) West Virginia University (1) Abramson Cancer Center at Penn Medicine (1) National Taiwan University Hospital (1) National Cancer Centre, Singapore (1) Idera Pharmaceuticals (1) Medical University of South Carolina (1) National Cancer Institute (NCI) (1) Brown University (1) Xingchen Peng (1) University of Oxford (1) TriSalus Life Sciences (1) Second Affiliated Hospital of Guangzhou Medical University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.